Design of a prodrug bispecific antibody masked by a functional molecule for lymphocyte activation for cancer therapy
Abstract Although T cells engaging bispecific antibodies (T-bsAbs) have shown great benefits, their use in treating solid tumors is challenging because of the minimal infiltration of T-cells. We fused an agonistic single-chain variable fragment (scFv) that induces a T cell co-stimulatory signal to t...
Saved in:
| Main Authors: | Daimei Miura, Yuki Kato, Masahiro Yasunaga, Izumi Kumagai, Ryutaro Asano |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Biological Engineering |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13036-025-00517-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity
by: Rikuto Nakamura, et al.
Published: (2025-06-01) -
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
Creation of anthracycline prodrug
by: A. N. Tevyashova
Published: (2014-12-01) -
The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma
by: Xiaoling Zhou, et al.
Published: (2025-08-01) -
Recent progress in stimuli‐activable metallo‐prodrugs for cancer therapy
by: Jinzhe Liang, et al.
Published: (2024-09-01)